References
Key articles
World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. 2005 [internet publication].Full text
King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep. 2003 Nov 21;52(RR-16):1-16.Full text Abstract
World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. 2005 [internet publication].Full text
King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep. 2003;52:1-16.Full text Abstract
Christopher PR, David KV, John SM, et al. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev. 2010 Aug 4;2010(8):CD006784.Full text Abstract
Reference articles
1. Kotloff KL, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ. 11999;77(8):651-66.Full text Abstract
2. Gastrointestinal infections and food poisoning. In: Bannister BA, Gillespie SH, Jones J. Infection: microbiology and management. 3rd ed. Oxford, UK: Blackwell Publishing Ltd.; 2006:167-201.
3. Centers for Disease Control and Prevention (CDC). National Shigella surveillance. 21 May 2018 [internet publication].Full text
4. Kotloff KL, Riddle MS, Platts-Mills JA, et al. Shigellosis. Lancet. 2018 Feb 24;391(10122):801-12. Abstract
5. GBD 2016 Diarrhoeal Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018 Nov;18(11):1211-28.Full text Abstract
6. Marder EP, Cieslak PR, Cronquist AB, et al. Incidence and trends of infections with pathogens transmitted commonly through food and the effect of increasing use of culture-independent diagnostic tests on surveillance - Foodborne Diseases Active Surveillance Network, 10 US sites, 2013-2016. MMWR Morb Mortal Wkly Rep. 2017 Apr 21;66(15):397-403.Full text Abstract
7. Schroeder GN, Hilbi H. Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev. 2008 Jan;21(1):134-56.Full text Abstract
8. Taylor CM. Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol. 2008 Sep;23(9):1425-31.Full text Abstract
10. Suzuki T, Sasakawa C. Molecular basis of the intracellular spreading of Shigella. Infect Immun. 2001 Oct;69(10):5959-66.Full text Abstract
11. Torres AG. Current aspects of Shigella pathogenesis. Rev Latinoam Microbiol. Jul-Dec 2004;46(3-4):89-97. Abstract
12. World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. 2005 [internet publication].Full text
13. King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep. 2003 Nov 21;52(RR-16):1-16.Full text Abstract
14. Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg. 2009 Apr;80(4):609-14. Abstract
15. Hill DR, Ryan ET. Management of travellers' diarrhoea. BMJ. 2008 Oct 6;337:a1746.Full text Abstract
16. Public Health England; Infection and infectious diseases: update on the epidemiology of Shigella in adults in London; 2012 to 2016. May 2017 [internet publication].Full text
17. Sansonetti PJ. Shigellosis: an old disease in new clothes? PLoS Med. 2006 Sep;3(9):e354.Full text Abstract
18. Kotloff KL, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ. 11999;77(8):651-66.Full text Abstract
19. Schroeder GN, Hilbi H. Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev. 2008 Jan;21(1):134-56.Full text Abstract
20. World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. 2005 [internet publication].Full text
21. King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep. 2003;52:1-16.Full text Abstract
22. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017 Nov 29;65(12):e45-80.Full text Abstract
23. Public Health England. Notifiable diseases and causative organisms: how to report. 26 October 2020 [internet publication].Full text
24. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000 Jun 29;342(26):1930-6. Abstract
25. Murphy MS. Management of bloody diarrhoea in children in primary care. BMJ. 2008 May 3;336(7651):1010-5.Full text Abstract
26. Razzaq S. Hemolytic uremic syndrome: an emerging health risk. Am Fam Physician. 2006 Sep 15;74(6):991-6.Full text Abstract
27. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005 Apr;16(4):1035-50.Full text Abstract
28. Centers for Disease Control and Prevention (CDC). CDC health information for international travel (yellow book) – shigellosis. 2019 [internet publication].Full text
29. Riddle MS, DuPont HL, Connor BA. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. Am J Gastroenterol. 2016 May;111(5):602-22.Full text Abstract
30. National Institute for Health and Care Excellence. Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management. April 2009 [internet publication].Full text
31. UNICEF/WHO. Diarrhoea: why children are still dying and what can be done. 2009 [internet publication].Full text
32. Rabbani GH, Ahmed S, Hossain I, et al. Green banana reduces clinical severity of childhood shigellosis: a double-blind, randomized, controlled clinical trial. Pediatr Infect Dis J. 2009 May;28(5):420-5. Abstract
33. Christopher PR, David KV, John SM, et al. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev. 2010 Aug 4;2010(8):CD006784.Full text Abstract
34. CDC Health Alert Network (HAN). CDC recommendations for diagnosing and managing Shigella strains with possible reduced susceptibility to ciprofloxacin. CDCHAN-0040. Apr 2017 [internet publication].Full text
35. Srinivasa H, Baijayanti M, Raksha Y. Magnitude of drug resistant Shigellosis: a report from Bangalore. Indian J Med Microbiol. 2009 Oct-Dec;27(4):358-60.Full text Abstract
36. Centers for Disease Control and Prevention (CDC) Health Alert Network (HAN). Update – CDC recommendations for managing and reporting Shigella infections with possible reduced susceptibility to ciprofloxacin. 7 June 2018 [internet publication].Full text
37. Allen GP, Harris KA. In vitro resistance selection in Shigella flexneri by azithromycin, ceftriaxone, ciprofloxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother. 2017 Jun 27;61(7):e00086-17.Full text Abstract
38. Folster JP, Pecic G, Bowen A, et al. Decreased susceptibility to ciprofloxacin among Shigella isolates in the United States, 2006 to 2009. Antimicrob Agents Chemother. 2011 Apr;55(4):1758-60. Abstract
39. Williams PCM, Berkley JA. Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence. Paediatr Int Child Health. 2018 Nov;38(sup1):S50-65.Full text Abstract
40. Howie RL, Folster JP, Bowen A, et al. Reduced azithromycin susceptibility in Shigella sonnei, United States. Microb Drug Resist. 2010 Dec;16(4):245-8. Abstract
41. Ezernitchi AV, Sirotkin E, Danino D, et al. Azithromycin non-susceptible Shigella circulating in Israel, 2014-2016. PLoS One. 2019;14(10):e0221458.Full text Abstract
42. Darton TC, Tuyen HT, The HC, et al. Azithromycin resistance in Shigella spp. in Southeast Asia. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e01748-17.Full text Abstract
43. Liu G, Qian H, Tang B, et al. Prevalence and characterisation of third-generation cephalosporin-resistant Shigella flexneri isolates from Jiangsu Province, China, 2013-2015. J Glob Antimicrob Resist. 2018 Dec;15:283-7. Abstract
44. Taneja N, Mewara A, Kumar A, et al. Cephalosporin-resistant Shigella flexneri over 9 years (2001-09) in India. J Antimicrob Chemother. 2012 Jun;67(6):1347-53.Full text Abstract
45. Costello AM, Bhutta TI. Antidiarrhoeal drugs for acute diarrhoea in children. BMJ. 1992 Jan 4;304(6818):1-2.Full text Abstract
46. Lazzerini M, Wanzira H. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev. 2016 Dec 20;12(12):CD005436.Full text Abstract
47. Collinson S, Deans A, Padua-Zamora A, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2020 Dec 8;(12):CD003048.Full text Abstract
48. Williams P, Berkley JA. Dysentery (Shigellosis) current guidelines and essential medicine list for children. November 2016 [internet publication].Full text
49. Tickell KD, Brander RL, Atlas HE, et al. Identification and management of Shigella infection in children with diarrhoea: a systematic review and meta-analysis. Lancet Glob Health. 2017 Dec;5(12):e1235-48.Full text Abstract
50. Hannu T, Mattila L, Siitonen A, et al. Reactive arthritis attributable to Shigella infection: a clinical and epidemiological nationwide study. Ann Rheum Dis. 2005 Apr;64(4):594-8.Full text Abstract
51. Gwee KA. Postinfectious irritable bowel syndrome. Curr Treat Options Gastroenterol. 2001 Aug;4(4):287-91. Abstract
52. Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol. 2009 Aug 7;15(29):3591-6.Full text Abstract
53. Public Health England. Shigella laboratory reports: 1992 to 2013. December 2012 [internet publication].Full text
Use of this content is subject to our disclaimer